B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PHKG1

MOLECULAR TARGET

phosphorylase kinase catalytic subunit gamma 1

UniProt: Q16816NCBI Gene: 526021 compounds

PHKG1 (phosphorylase kinase catalytic subunit gamma 1) is targeted by 21 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PHKG1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1gefitinib5.67290
2alvocidib4.5291
3tozasertib4.3375
4vandetanib4.3073
5ruxolitinib4.2368
6bosutinib4.0858
7midostaurin3.8546
8nintedanib3.6136
9pelitinib3.5032
10bms 3870323.4731
11tae 6843.4330
12fedratinib3.4029
13dovitinib3.0921
14lestaurtinib3.0420
15ruboxistaurin2.9418
16pha 6657522.7114
17kw 24492.6413
18su 0148132.208
19enzastaurin2.087
20sra 7371.956
21Afatinib0.691

About PHKG1 as a Drug Target

PHKG1 (phosphorylase kinase catalytic subunit gamma 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 21 compounds with documented PHKG1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PHKG1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.